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Hysterectomy is the commonest gynecologic operation performed not only for malignant disease but also for many benign
conditions such as ﬁbroids, endometrial hyperplasia, adenomyosis, uterine prolapse, dysfunctional uterine bleeding, and cervical
intraepithelial neoplasia. There are many approaches to hysterectomy for benign disease: abdominal hysterectomy, vaginal
hysterectomy, laparoscopic assisted vaginal hysterectomy (LAVH) where a vaginal hysterectomy is assisted by laparoscopic
procedures that do not include uterine artery ligation, total laparoscopic hysterectomy (TLH) where the laparoscopic procedures
include uterine artery ligation, and subtotal laparoscopic hysterectomy (STLH) where there is no vaginal component and
the uterine body is removed using a morcelator. In the last decades, many new techniques, alternative to hysterectomy with
conservation of the uterus have been developed. They use modern technologies and their results are promising and in many
cases comparable with hysterectomy. This paper is a review of all the existing hysterectomy techniques and the alternative methods
for benign indications.
1.Introduction
The term hysterectomy originates from two Greek words:
“hystero” which means uterus and “ectomy” which means
resectionremovalfromthehumanbody.Thissurgicalproce-
dure is indicated in several common gynecologic problems.
Hysterectomy is either total or subtotal, with or without the
adnexae and depended on the way performed: abdominal,
vaginal and laparoscopic or laparoscopic assisted vaginal
hysterectomy. Historically the ﬁrst vaginal hysterectomy was
performed by Conrad Langenbeck in 1813, the ﬁrst subtotal
abdominal hysterectomy by Walter Burnham in 1853, the
ﬁrstelectiveabdominalhysterectomybyClayandKoeberlein
1863, and the ﬁrst laparoscopic hysterectomy by Harry Reich
in 1988.
2.MaterialandMethods
There are several indications for hysterectomy or the alterna-
tive procedures with preservation of the uterus which will be
analyzed in detail. In this paper, only benign conditions will
be reviewed.
2.1. Fibroid Uterus. Fibroids (myomas) originate from the
uterine smooth muscle wall. The percentage of malignant
transformation to sarcoma is 0,1–0,8% according to various
references. Fibroids, depending on size and location can
cause menorrhagia or symptoms from pressure to adjacent
organs, for example, ureters, bladder, or intestine. Before
proceedingtohysterectomyforaﬁbroiduterus,reproductive
activity of the patient must be completed.
2.1.1. Surgical Approach
(I) Abdominal Hysterectomy:
(a) Total:withorwithoutbilateralsalpingoophorectomy.
(b) Subtotal: with or without bilateral salpingoophorec-
tomy.
(II) Laparoscopic Hysterectomy:
(a) Total:( + /− initially laparoscopic myomectomy for
reduction of the uterine volume): with or without
bilateral salpingoophorectomy.
(b) Subtotal: with or without bilateral salpingoophorec-
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(III) Laparoscopic Assisted (Total) Vaginal Hysterectomy
(LAVH). (+/− initially laparoscopic myomectomy for
reduction of the uterine volume): with or without bilateral
salpingoophorectomy.
(IV) Vaginal (Total) Hysterectomy: with or without bilateral
salpingoophorectomy.
2.1.2. Alternative Methods
(I) Myomectomy:
(a) via laparotomy,
(b) via laparoscopy.
(II) Uterine artery embolism (UAE).
(III) Transvaginal Temporary Uterine Artery Occlusion.
(IV) MRI-Guided Focused Ultrasound (MRgFUS).
(V) Medical treatment (progesterone mifepristone and
asoprisnil under investigation).
2.2. Endometrial Hyperplasia. Endometrial hyperplasia with
atypia associated with a high risk for malignant trans-
formation, is an absolute indication for hysterectomy. In
endometrial hyperplasia without atypia, hysterectomy is
indicated only if pharmacological agents cannot control
menorrhagia.
There are four categories of endometrial hyperplasia:
(a) simple hyperplasia without atypia,
(b) complex hyperplasia without atypia,
(c) simple hyperplasia with atypia,
(d) complex hyperplasia with atypia.
2.2.1. Surgical Approach
(I) Abdominal Hysterectomy:
(a) Total:withorwithoutbilateralsalpingoophorectomy.
(b) Subtotal: with or without bilateral salpingoophorec-
tomy.
(II) Laparoscopic Hysterectomy:
(a) Total:withorwithoutbilateralsalpingoophorectomy.
(b) Subtotal: with or without bilateral salpingoophorec-
tomy.
(III) Laparoscopically Assisted (Total) Vaginal Hysterectomy
(LAVH): with or without bilateral salpingoophorectomy.
(IV) Vaginal (Total) Hysterectomy: with or without bilateral
salpingoophorectomy.
2.2.2. Alternative Methods
Operative hysteroscopy and resection of the endometrium
(endometrectomy) using a resectoscope in case of hyper-
plasia without atypia (Trans Cervical Resection of the
Endometrium—TCRE),
Operative hysteroscopy and cauterization of the
endometrium using a resectoscope in case of hyperplasia
without atypia (Rollerball),
Thermal uterine balloon therapy system for endometrial
ablation in case of hyperplasia without atypia,
M e d i c a lt r e a t m e n t( p h a r m a c o l o g i c a la g e n t ss u c ha sp r o -
gesterone) in case of hyperplasia without atypia,
Insertion of levonorgestrel hormone releasing intrauter-
ine device (LNG-IUD) in case of hyperplasia without atypia.
2.3. Adenomyosis. A benign condition of the uterus which
can cause menorrhagia characterized by diﬀuse spread of
ectopic endometrium in the myometrium. Hysterectomy is
indicated when other therapeutic approaches have failed to
control symptoms.
2.3.1. Surgical Approach
(I) Abdominal Hysterectomy:
(a) Total:withorwithoutbilateralsalpingoophorectomy.
(b) Subtotal: with or without bilateral salpingoophorec-
tomy.
(II) Laparoscopic Hysterectomy:
(a) Total:withorwithoutbilateralsalpingoophorectomy.
(b) Subtotal: with or without bilateral salpingoophorec-
tomy.
(III) Laparoscopic Assisted (Total) Vaginal Hysterectomy
(LAVH): with or without bilateral salpingoophorectomy.
(IV) Vaginal (Total) Hysterectomy: with or without bilateral
salpingoophorectomy.
2.3.2. Alternative Methods
Adenomyomatectomy via laparotomy or laparoscopy.
Combination of hysteroscopic resection of the
endometrium (Trans Cervical Resection of the Endome-
trium—TCRE) and hysteroscopic cauterization to the
endometrium with the Rollerball device.
2.4. Uterine Prolapse. It is not an absolute indication for
hysterectomy. In case of absence of other uterine pathology
(suchassarcoma,carcinomaoftheendometrium,carcinoma
of the cervix) the translocation of the uterus in its natural
position and the surgical ﬁxation of the uterus in the pelvis
have better results than hysterectomy in the anatomy of the
pelvic ﬂoor.
2.4.1. Surgical Approach
(I) Total Hysterectomy:
(a) Abdominal Total: with or without bilateral salpin-
goophorectomy.
(b) Vaginal Total: with or without bilateral salpin-
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(c) Laparoscopic Total: with or without bilateral salpin-
goophorectomy and sacrocolpopexy or lateral ﬁxa-
tion of the vaginal vault using the J.B. Dubuisson
method (using a polypropylene mesh). Laparoscopic
approach is accompanied with a “Burch” or a “free
Tension Vaginal Tape” procedure.
(d) Laparoscopic assisted total vaginal hysterectomy:w i t h
or without bilateral salpingoophorectomy.
(II) Subtotal Hysterectomy: Only in Cases That Cervical
Pathology, for Example, CIN or Cervical Carcinoma Has
Been Excluded
(a) via laparotomy + cervicosacropexy,
(b) via laparoscopy + cervicosacropexy or lateral ﬁxation
ofthecervicalstumpusingtheJ.B.Dubuisonmethod
(using a polypropylene mesh).
2.4.2. Alternative Methods.
Conservation of the Uterus: When Other Uterine Pathology
Has Been Excluded and the Only Problem Is the Prolapse.
(a) Fixation of the uterine ligaments by laparotomy or
laparoscopy.
(b) Fothergill isthmical uteropexy (Manchester repair) in
case of simple elongation of the cervix.
(c) Isthmical sacropexy (sacrocolpopexy) by laparotomy
or laparoscopy.
(d) Kapandji procedure.
(e) Colpoclisis.
2.5. Dysfunctional Uterine Bleeding (DUB). This common
cause of abnormal uterine bleeding pattern is diagnosed
when anatomical causes have been excluded. The problem
is a hormonal imbalance in the hypothalamus-hypophysis-
gonads axis.
2.5.1. Surgical Approach
(I) Abdominal Hysterectomy:
(a) Total:withorwithoutbilateralsalpingoophorectomy.
(b) Subtotal: with or without bilateral salpingoophorec-
tomy.
(II) Laparoscopic Hysterectomy:
(a) Total:withorwithoutbilateralsalpingoophorectomy.
(b) Subtotal: with or without bilateral salpingoophorec-
tomy.
(III) Laparoscopic Assisted (Total) Vaginal Hysterectomy
(LAVH): with or without bilateral salpingoophorectomy.
(IV) Vaginal (Total) Hysterectomy: with or without bilateral
salpingoophorectomy.
2.5.2. Alternative Methods
(a) Insertion of levonorgestrel hormone-releasing intra-
uterine device (LNG-IUD).
(b) Rollerball electrocoagulation (RBE).
(c) Nd:YAG laser ablation.
(d) Transcervical resection of endometrium (TCRE).
(e) Thermal uterine balloon therapy system for endome-
trial ablation.
(f) Global 3D Bipolar Ablation Method.
(g) Punctual Vaporizing Method.
(h) Endometrial Ablation by Intrauterine Instillation of
Hot Saline.
(i) Diode Laser Method.
(j) Photodynamic Therapy.
(k) Microwave Method.
(l) Radiofrequency Method.
(m) Cryotherapy Method.
2.6. High Grade Cervical Intraepithelial Neoplasia (CIN III).
In younger patients who have not completed their family
an excision of the transformation zone using electrocautery
(LLETZ) or a classical conisation of the cervix using scalpel
or laser is indicated. In older patients who have completed
their family, trachelectomy or even an abdominal hysterec-
tomy with or without the ovaries is indicated.
A review of all the existing and especially the new
techniques of hysterectomy and its alternatives follows.
(1) Total laparoscopic hysterectomy (TLH) with or with-
out salpingoophorectomy.
(2) Subtotal laparoscopic hysterectomy (STLH) with or
without salpingoophorectomy.
(3) Laparoscopic assisted vaginal hysterectomy (LAVH)
with or without salpingoophorectomy.
(4) Laparoscopic adenomyomectomy in case of focal
adenomyosis.
(5) Isthmical sacropexy (sacrocolpopexy with conserva-
tion of the uterus).
(6) Cervicosacropexy after laparoscopic subtotal hys-
terectomy.
(7) Lateral ﬁxation of the cervical stump or the vaginal
vault (J.B. Dubuisson method).
(8) Uterine artery embolism (UAE) in case of uterine
ﬁbroids.
(9) Ttansvaginal temporary uterine artery occlusion.
(10) MRI guided focused ultrasound (MRgFUS).
(11) Hysteroscopic (transcervical) resection of the en-
dometrium (endometrectomy) with resectoscope
(TCRE).
(12) Hysteroscopic cautery to the endometrium with
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(13) Nd-YAG Laser Ablation.
(14) Thermal uterine balloon therapy system for endome-
trial ablation.
(15) Global 3D Bipolar Ablation Method.
(16) Punctual Vaporizing Method.
2.6.1. Total Laparoscopic Hysterectomy (TLH)
Position
The patient is placed in the supine position with both hands
on her sides using extension tubes for intravenous access.
Her knees slightly bended to avoid pressure. Calves slightly
turned laterally. Rumps 10cm outside the operation table
edges. The height of the operation table 30cm lower than
in classical laparotomy. Upper limbs insulated from the
operating table.
proceduree
Thereareplacementoftheuterinemanipulatordevice.Small
incision vertical or round on the lower edge of the umbilicus
10mm in length. Insertion of the Veress needle. Security test
using a syringe. Inﬂation of the peritoneal cavity through the
veress needle with CO2. The pressure limit is 14–18mmHg.
Insertion of the main trocard 10mm wide and through
that insertion of the laparoscope and inspection of the
whole peritoneal cavity. There are placement of the patient
in trendelenbourg position and insertion of the lateral
trocards (5mm width) trying to avoid the epigastric vessels
(superﬁcial and deep) and umbilical arteries. Placement of
the middle operating trocard (5mm width) above the pubis
symphysis. The left round ligament is grasped and uterus
is turned onto the other side in order to put tension on it.
The round ligament is coagulated using bipolar diathermy
and cut using scissors. The parametrium is opened and the
frontalsheathiscuttotheuterine-urinarybladderperitoneal
fold. A “window” is opened on the posterior sheath of
the broad ligament. The same procedure on the right side.
Ovarian ligaments or suspensor ligaments (depending on
the indication) are grasped, coagulated and cut. The uterine-
urinary bladder peritoneal fold is grasped, divided and cut to
the lateral edge. The frontal vaginal vault then appears. The
ascending and descending branches of the uterine arteries
are found in the parametrium, coagulated with bipolar
diathermy and cut. Uterosacral ligaments are grasped and
cut where they conjoint. Vaginal vault is presented using
the manipulator and a circular incision is performed and
uterus can now be removed through the vagina. Uterus is
placed in the vagina so that inﬂation of the abdomen is not
disturbed. Vaginal vaultiscoagulatedonly mildly in bleeding
spots to avoid tissue necrosis. Suturing of the vaginal vault
edges and uterosacral ligaments (2 stitches in the ankles).
Checking of the haemostasis. Removal of the instruments
and the pneumoperitoneum. Suturing of the wounds where
trocards were placed.
2.6.2. Subtotal Laparoscopic Hysterectomy (STLH). The dif-
ferences between this procedure and Laparoscopic total
hysterectomy are listed below. (1) When parametrium is
dividedwestopattheisthmuswhereuterinearteryisdivided
in her ascending and descending branches. Thermal ligation
is performed only for the ascending branches. (2) Circular
incision is performed round the isthmus and not around the
vaginalvault.(3)Uterinebodyisremovedusingamorcelator
through the middle operative trocard and not through the
vagina as in total hysterectomy. (4) Ovaries are placed in a
laparoscopic bag when removed. (5) Uterosacral ligaments
are not incised. (6) Suturing of the cervical stump and not of
the vaginal vault is performed.
2.6.3. Laparoscopic Assisted Vaginal Hysterectomy (LAVH).
In this procedure, laparoscopic approach is used only for
the ligation and incision of the round ligaments and the
suspensory or ovarian ligaments whether ovaries are going
to be removed or not. Ligation and incision of the uterine
arteries and the rest of the procedure is performed through
the vaginal route.
2.6.4. Laparoscopic Adenomyomectomy (Focal Adenomyosis).
Excision of adenomyomas can be performed using the
laparoscopicapproachbutiscompletelydiﬀerentwhencom-
pared to the laparoscopic myomectomy. Surgical procedure
is certainly more diﬃcult because adenomyomas have no
clear margins from the normal uterine smooth muscle wall.
In certain occasions the surgeon is obliged to perform a
tumor reduction operation and remove only part of the
mass. Another diﬀerence comparing with myomectomy is
the tissue deﬁcit that the surgeon has to deal with when
adenomyoma is removed and the deﬁcit has to be sutured.
There are very few references in the international literature
but the results of this operation seem promising even when
it is performed as a mass-reduction operation.
2.6.5. Laparoscopic Isthmical Sacropexy (Sacrocolpopexy with
Conservation of the Uterus). There are two diﬀerent tech-
niques. The ﬁrst is described as lateral ﬁxation only of the
right side due to the presence of rectum and sigmoid colon
on the left side. The second referred as “Scali” technique is
described as bilateral ﬁxation using a “V” shaped mesh. This
technique is described below.
ThereAreThreeBasicPrinciples. (a)Suspensionoftheuterus
in its normal position and ﬁxation of the pelvic ﬂoor below
the urinary bladder. (b) Treatment of the stress incontinence
even if the patient is asymptomatic. The reason is that
suspension of the uterus will reveal or worsen the stress
incontinence. (c) Surgical reconstruction of the rectovaginal
diaphragm.
SurgicalProcedure. Thereisincisionontheperitoneum1cm
below the urinary bladder—uterine peritoneal fold. The
space between the bladder and uterus is exposed and the
bladder is pulled downwards. These space’s lateral margins
(pillars) are joined inferiorly in the height of the posteriorObstetrics and Gynecology International 5
Table 1: Alternative to hysterectomy methods for benign disease.
Laparoscopic adenomyomectomy in case of focal adenomyosis
Isthmical sacropexy (sacrocolpopexy with conservation of the uterus)
Cervicosacropexy after laparoscopic subtotal hysterectomy
Lateral ﬁxation of the cervical stump or the vaginal vault (J.B. Dubuisson method)
Uterine artery embolism (UAE) in case of uterine ﬁbroids
Ttansvaginal temporary uterine artery occlusion
MRI guided focused ultrasound (MRgFUS)
Hysteroscopic (transcervical) resection of the endometrium (endometrectomy) with resectoscope (TCRE)
Hysteroscopic cautery to the endometrium with resectoscope (Rollerball)
Nd-YAG Laser Ablation
Thermal uterine balloon therapy system for endometrial ablation
Global 3D Bipolar Ablation Method
Punctual Vaporizing Method
urethra. The vaginal wall is exposed and the broad ligament
is opened at the isthmus far away from the uterine arteries.
A wide window is opened in the posterior fold of the broad
ligament. The peritoneum between the uterosacral ligaments
is opened to 1cm above the point the two uterosacral
ligaments joint together (“Λ” point). The sacral promontory
(L5-S1 space), the iliac veins and the ureters are recognized.
The peritoneum covering the sacrum is opened and anterior
elongated ligament and middle sacral vessels are recognized.
The latest are coagulated only if they cannot be removed
from the points that stitches are to be placed. Opening of the
peritoneumcontinuestothepointthatuterosacralligaments
joint. A “V” shaped mesh is inserted through the middle
operating trocard (10–12mm). The wide part of the mess is
placed in the space in front of the urinary bladder and the
sidesareplacedthroughthewindowsin thebroadligaments.
The sides of the mess are barried behind the uterus at the
isthmus. The two pararectal spaces are opened, suspensory
muscles of the rectum are recognized and the sides of the
mesh are ﬁxed in this space and the Cardinal ligaments. The
mesh is sutured on the vaginal wall using 2/0 nonabsorbable
stitches with a 23mm needle (6–8 stitches). Restoration
of the peritoneum only in the rectovaginal space follows.
Then sacropexy is performed. The two sides of the mesh
are ﬁxed on the anterior longitudinal ligament of the spine
with two stitches using no1 nonabsorbable stitches with a
30mm needle. Special attention is needed to avoid injury
of the intervertebral disk. Restoration of the peritoneum is
completed in order to cover the mesh in the retroperitoneal
space.
After completion of the procedure, a Burch colposuspen-
sion or a tension-free vaginal tape application is performed
for the reasons already mentioned. In case stress incon-
tinence is due to sphincter failure Burch colposuspension
is not indicated and a tension-free vaginal tape has to be
applied. At the end a typical posterior repair is performed.
Complications:
(a) When opening the space in front of the urinary
bladder, injuries to the bladder are common. Injuries
to the ureters are more uncommon.
(b) When opening the broad ligaments, the sigmoid
colon can be injured.
(c) When opening the recto-uterine space, the rectum
can be injured.
(d) When the anterior longitudinal ligament is prepared,
bowel, ureters, middle sacral artery, and left iliac vein
can be injured.
(e) Infection of the mesh.
2.6.6. Cervicosacropexy after Laparoscopic Subtotal Hysterec-
tomy. During the time of uterus removal from peritoneal
cavity, the mesh that is going to be used (polypropylene Type
1) is drawn and cut out. It is inserted through the medial
operating trocard and detained on the cervical stump with
staplers and four sutures using nonabsorbent stitch 1, with
23mm needle.
Opening of the peritoneum in front of the anterior
elongated ligament and opening of a “channel” between this
andthecervicalstump.Themeshinsertedwithinthechannel
and ﬁxation on the anterior elongated ligament with staplers
and two sutures using nonabsorbent stitch. Restoration of
the peritoneum follows.
After completion of the operation, Burch colposuspen-
sion or insertion of a tension-free vaginal tape is needed. In
cases that urine incontinence is due to sphincter deﬁciency,
Burch procedure has no place and the placement of a
tension-free vaginal tape would be preferable. Finally, a
typical posterior repair is performed.
2.6.7. Laparoscopic Lateral Fixation with the Use of Synthetic
Mesh (J.B. Dubuisson Method)
(A) Of Cervical Stump (After Laparoscopic Subtotal Hys-
terectomy). During the time of uterus removal from the
peritoneal cavity, the mesh that is going to be used
(polypropylene Type 1) is drawn and cut out in two elon-
gated parts. These two parts are inserted in the peritoneal
cavity through the suprapubic operative trocard and are
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stump using stapler and four nonabsorbent stitches 1, with
23mm needle follows. A needle holder is inserted over the
iliac promontory on the left,twoto three centimeters outside
the side trocard. Forward this up to the parietal peritoneum.
Forward outside the peritoneum until meeting the one side
of the mesh. The side of the mesh is grasped and pulled
up to the skin and ﬁnally ﬁxed with a small grasper. The
same surgical procedure to the other side. Restoration of
the peritoneum over the cervical stump. Pulling of the sides
of the plexus- ﬁxing on the sheath of the external oblique
a b d o m i n a lm u s c l ew i t hn o n a b s o r b e n ts t i t c h e s .
Similarly to the classical sacropexy, a Burch colposuspen-
sion or insertion of a tension-free vaginal tape is needed
afterwards. If incontinence is due to sphincter deﬁciency,
Burch operation has no use and the placement of a tension-
free tape would be preferable. Finally, a typical posterior
repair suture is performed.
(B) Of Vaginal Stump (After Laparoscopic Total Hysterec-
tomy). It is the same surgical technique. The only diﬀerence
isthatthemeshisﬁxedonthevaginalandnotonthecervical
stump.
2.6.8. Uterine Artery Embolization (UAE). It is a transcu-
taneous, X-Ray guided technique, performed by specialists
in intervention-radiography [1]. An angiography catheter
is inserted in the uterine arteries through one of the two
common femoral arteries. Infusion of the embolic agents
(polyvinyl alcohol particles or tris-acryl gelatin micro-
spheres) follows in the two uterine arteries until their blood
ﬂow decelerates [1–7].
The mechanism of UAE is the irreversible ischemic
necrosis of the ﬁbromyomas caused by the crucial decrease
of the blood ﬂow, having as a result their necrosis, while
the rest of the normal myometrium is capable of surviving
[8, 9]. The whole procedure takes place under intravenous
anesthesia and lasts approximately one hour.
The recovery is brief and relatively mild, with 4-5 days
of recurrent uterine cramping and constitutional symptoms
(nausea malaise, fatigue and low-grade fever). Patients
can usually return to normal activities within 8–14 days
[6, 10–13].
UAE technique was ﬁrst described in 1995 [2]. Several
studies show a 50–60% decrease in ﬁbroids dimensions and
also a decrease in menorrhagia and the rest of the symptoms
relatedtotheminapercentagethatreaches85–95%inshort-
and middle-term follow-up [3, 5–7, 10, 14–20].These studies
also report 87–97% patient satisfaction after the procedure.
With concern to the mild complications, according the
perspectivestudyFIBROIDregistry,apercentageof2,7%(90
out of 3041 patients) in the immediate postoperative period
and 26% (710 out of 2729 patients) after the hospital exit
are reported. The percentages of the severe complications are
0,6% and 4,1%, respectively, [13].
A common complication of UAE is the infracted ﬁbroid
to become endocavitary and “aborted” through the vagina
(approximately in 10% of the cases) [6, 21]. According to
Fred Burbank [22], this is not a complication, if the patient
is well informed and ready to consider this as part of the
procedure. In any case, this is usually reported after UAE
for submucosal ﬁbroids or ﬁbroids lying within the uterine
wall and protruding inside the uterine cavity. According
to the literature the “abortion” of such ﬁbroids can take
place within 6 months and 4 years [23]. Most of the times
the “abortion” is spontaneous while in some cases cervical
dilation or even hysteroscopic removal is needed when the
ﬁbroid remains connected to the uterus.
The most serious complication of UAE is endometritis
(less than 1%) [3, 6, 10, 11, 13, 24], which if left without
antimicrobial prophylaxis could lead to sepsis, or even death
(∼0,05/1000) [25].
Concerning the failure rate of the procedure, according
to the FIBROID registry study after three years of follow-
up there was a need for hysterectomy, myomectomy or a
repeat UAE procedure in 9,8%, 2,8% and 1,8%, respectively,
[26]. The need for a repeat operation is not only due to new
ﬁbroids but also due to incomplete infarction of the old ones
[27]. The successful embolization of only one uterine artery
is considered as a technical failure of the procedure, since in
most of the cases the blood ﬂow to the ﬁbroids derives from
both the uterine arteries [28]. There is also dispute among
several studies whether the size or the number of ﬁbroids are
predictive factors of possible failure [29].
Uterine artery embolization (UAE) for ﬁbroids has
been extensively investigated. Since 1995 when was ﬁrst
introduced and particularly in the last 5 years, several high-
qualitystudiesreportedonitsoutcomehavebeencompleted.
These studies have demonstrated that when successful, UAE
can provide symptom control similar to surgery. Although
hysterectomy remains more eﬀective in symptom control
and durability, many women are seeking uterine-sparing
alternatives. UAE has emerged as the leading minimally
invasivetreatmentforﬁbroids:Morbidityislowandrecovery
rapid; serious complications are quite rare. With a few
anatomical exceptions, UAE is appropriate for most patients
with symptomatic ﬁbroids who have completed childbear-
ing [30]. Although pregnancy is certainly possible after
embolization [30–32] existing data suggest better reproduc-
tive outcomes for myomectomy in the ﬁrst 2 years after
treatment. The current recommendation is for myomectomy
as a ﬁrst choice for patients seeking to become pregnant.
2.6.9. Transvaginal Temporary Uterine Artery Occlusion. It
is an alternative method targeting to decrease the blood
ﬂow in the uterine arteries in order to treat ﬁbroids. The
theorysupportingthistechniqueisthataﬁbroidnecrosiscan
take place after temporary occlusion of uterine arteries and
temporary uterine ischemia that follows [33, 34]. It demands
special equipment and the duration of the procedure is 6
hours. Immediately after the procedure the ﬁbroids and the
uterine volume decreases 40-50%. In 6 months follow-up,
the symptoms improved 80–90%.
Comparing transvaginal temporary uterine artery occlu-
sion with uterine artery embolization, in this technique there
is no exposure to radiation and the patients has much less
postoperative pain. Although the short-term results seem to
be similar to UAE, the long-term results are insuﬃcient since
theischemiaismuchweakercomparedtoembolization [29].Obstetrics and Gynecology International 7
2.6.10. MRI Guided Focused Ultrasound (MRgFUS). It is a
new, minimal interventional method of thermal destruction
of ﬁbroids, approved by the US Food and Drug Adminis-
tration (FDA) since 2004. High frequency ultrasound waves
penetrate the anterior abdominal wall and focus in a speciﬁc
target inside the ﬁbroid increasing the temperature up to 55–
90◦C, which leads to necrosis (coagulative necrosis) within a
few seconds. The simultaneous use of MRI allows the exact
focus on the target and real-time temperature feedback [35–
37]. The technique demands special equipment, has to be
performed by an expertised specialist and under intravenous
anesthesia [29].
T h em e t h o di sb a s e do nc c o n s e c u t i v ee x p o s u r e st o
focused sonications (ultrasound energy), lasting 20 seconds
each and resulting in a small (0.5cm3) bean-shaped ablated
volume. There is a pause of 90s to elapse for the tissue
to return to its baseline temperature, between sonications.
Multiple sonications are required to cover the entire target
volume, which is typically limited to a maximum of 150cm3
of tissue, and total procedure time is usually over 3 hours.
During the procedure short-term lower abdominal pain, leg
pain and buttock pain are common. Patients are usually
discharged home 1 hour after the procedure and return to
usual activities, on average, within 48 hours [35].
After taking into account that the total number of
patients treated with MRgFUS is very small worldwide,
its assessment and comparison with other techniques are
unsafe. Although compared to UAE there is no exposure
to radiation and the postoperative pain is less, in MRgFUS
there are constrictions concerning the volume and the
number of ﬁbroids. There is a relation between time and
total volume of ﬁbroids. This technique also has minor
results concerning the decrease of the uterus and ﬁbroid
volume [29]. The existence of some special characteristics,
likeﬁbroidsneighboringbloodvesselsandnervesorsensitive
organs like bowel or urinary bladder, diminishes the number
of candidates for the method [36]. Preservation of fertility
after MRgFUS is not well documented. It is interesting
that the procedure is more successful when a three months
treatment with GnRH-agonists precedes, so as for the ﬁbroid
blood ﬂow to be decreased [38].
2.6.11. Hysteroscopic (Transcervical) Resection of the Endome-
trium (Endometrectomy) with Resectoscope (Transcervical
Resection of the Endometrium-TCRE). In about 20–25% of
hysterectomies the indication is menorrhagia without any
obvious pathology. TCRE was ﬁrst described in 1983 from
DeCherney and Polan [39], and is still considered as the gold
standard alternative method since it combines histological
diagnosis and eﬀective treatment. Its target is the resection of
the whole endometrium, including basic layer. It is suitable
for patients who do not respond to medical treatment, do
not want hysterectomy and are not in reproductive age.
Before the procedure, malignant disease and atypia in cases
of endometrial hyperplasia should be excluded. TCRE is
combined with the use of rollerball for the destruction of the
endometrium in special spots like fundus and areas around
tubal ostia. Preoperative treatment with GnRH-agonists or
danazol is not necessary. Postoperatively, the placement of
levonorgestrel hormone-releasing intrauterine device (LNG-
IUD) has been proposed. Especially in adenomyosis cases
this combination increases the success rate of the proce-
dure. In a brief description, endometrium resection starts
from the fundus to the isthmus of the uterus clockwise.
The resection ends to the isthmus because of the risk of
subsequent haematometra. As already mentioned the fundus
is coagulated using rollerball along with the tubal ostia and
the whole area of endometrial resection [40].
2.6.12. Hysteroscopic Cauterization of the Endometrium with
Resectoscope (Rollerball)
First Generation Endometrial Ablation Method. The tech-
nique was ﬁrst described by Vancaille in 1989 [41]a n da s
TCRE, is among the most eﬀective ﬁrst generation methods,
done under hysteroscopic guidance. It is important that
the endometrium should be as thin as possible, when
applied. That is why follicular phase of the menstrual cycle
is preferred. The results are even better if GnRH- agonists
or danazole are administered for one or two cycles before
the operation [42]. The success rate (amenorrhea) after the
procedure reaches 100% against 75% without any previous
pharmaceutical treatment, the operative time is less because
of better visibility, the patients safety and the surgeons
eﬀortlessness much greater. It is suitable for these patients
w h od on o tr e s p o n dt op h a r m a c e u t i c a lt r e a t m e n t ,d on o t
want hysterectomy and are not in reproductive age. Before
the procedure malignancy and atypia should be excluded.
The technique uses monopolar energy at 60–80 Watt in
order to destroy the endometrium through coagulation
or at 160 watt to destroy it through vaporization. The
percentage of the remnant functional endometrium rates
at 70% [43]. So it would be favorable for the patient to
administer a combination of estrogen-progesterone or to
place a levonorgestrel hormone-releasing intrauterine device
(LNG-IUD).
It seems that the combination of the two methods
(TCRE-ROLLERBALL) is the gold standard when concern-
ing the endometrium destruction and the avoidance of
hysterectomy [40]. Mistletoe study which included 16087
patients in the United Kingdom, showed less complications
with the usage of rollerball in diﬃcult to reach with the loop
spots,likefundusandthetubalostia.Thesamestudyshowed
that 75–85% of the patients were very satisﬁed [44, 45].
2.6.13. Nd-YAG Laser Ablation
First Generation Endometrial Ablation Method. It was intro-
ducedin1981byGoldrathetal.[46].Itrequirespreoperative
hormonal treatment to assure that the endometrium is thin
and atrophic. During the procedure there is no use of electric
energy and Normal Saline or Dextrose 5% in 50% Saline or
Ringer’s Lactate Solution is used to dilate the endometrial
cavity. There are three techniques: dragging or touching
(touch technique), blanching (nontouch technique) and
dragging and blanching in combination (combination tech-
nique). There is no bleeding because the treatment is strictly
by coagulation. In order to avoid meeting the same areas8 Obstetrics and Gynecology International
twice there is need for strict charting of the endometrial
cavity.Themostcommontechniqueusedisthecombination
technique; nontouch technique is used in the cornea areas
andtouchtechniqueintherestoftheendometrialcavity.The
disadvantage of Nd-YAG Laser ablation is that it is expensive
because of the need for single-use optical ﬁbers [40].
2.6.14. Thermal Uterine Balloon Therapy System for
Endometrial Ablation
Second Generation Endometrial Ablation Method. There are
many companies manufacturing such systems of thermal
endometrial destruction. The technique uses the successful
heating of some dilative liquid within the balloon that is
placed inside the endometrial cavity. The procedure lasts
about 8 to 15 minutes depending on the manufacturing
company and the success rate of endometrial destruction
varies in diﬀerent studies. The temperature of the liquid
inside the balloon ranges from 75–80◦Ct o8 7+5 ◦C
depending again on the manufacturer. Although the pro-
cedure takes place without hysteroscopic guidance and is
characterized as “blind”, this second generation technique
is safe because the strict observation of all the crucial
parameters for the patient’s safety. Before the procedure
the existence of endometrial polyps or ﬁbroids, congenital
anomalies of the uterus, pregnancy, pelvis inﬂammation,
endometrium hyperplasia with atypia and malignancies of
the endometrium or the cervix should be excluded. This
method should take place during the follicular phase of the
menstrual cycle [40].
2.6.15. Global 3D Bipolar Ablation Method
Second Generation Endometrial Ablation Method. In this
techniqueathree-dimensiondoublepolardeviceisused.The
device is connected to a RF generator and causes ablation
by coagulation of the endometrium and the superjacent
myometrium in a certain set depth. The diameter of the
device is 6,5mm. The power of the generator is ﬁxed to
180W. It is completed in about one minute and does not
demand previous hormonal treatment. The success rate
(amenorrhea) is about 80% [40].
2.6.16. Punctual Vaporizing Method
Second Generation Endometrial Ablation Method. This tech-
nique uses vaporization and not coagulation of the
endometrium. Two diﬀerent devices are manufactured by
two diﬀerent companies. The ﬁrst uses monopolar energy,
the second bipolar. These devices can perform desiccation,
vaporization or blended cut depending on the generator
adjustment. Their use is not only restricted to endometrial
destruction, but can be used in the treatment of submucosal
ﬁbroids, polyps and adhesiolysis. The advantage of the
bipolar device is the use of Normal Saline for dilatation
which makes it safer even in the procedure lasts longer [40].
Other Second-Generation Endometrial Ablation Meth-
ods are: Endometrial Ablation by Intrauterine Instillation of
Hot Saline, Diode Laser Method, Photodynamic Therapy,
Microwave Method, Radiofrequency Method, and Cryother-
apy Method.
3. Discussion
Independently the technique used, hysterectomy is one of
the most common gynecological procedures. There are
certain diﬀerences comparing various techniques related
to indications, advantages and disadvantages. Abdominal
hysterectomy, the most well established method, permits
the surgeon to deal with any kind of pathology malignancy
included, and has the beneﬁt of the direct touch on the
tissues.Italsooﬀersthe beneﬁt ofthe direct three-dimension
visualization of the surgical ﬁeld and additionally does not
warrant expensive special instruments. On the other hand,
laparoscopic approach is not indicated for malignant disease
due to the hazard of spreading malignant cells by the gas
(CO2) used to inﬂate the abdominal cavity, there is no
direct touch on the tissues and warrants specialized surgeons
and expensive instruments and equipments. Visualization is
in two dimensions which require familiarization with the
technique. Despite the disadvantages, laparoscopic approach
oﬀers better view of the whole abdominal cavity, magniﬁ-
cation, enhanced ability to perform delicate manipulation
of the tissues, blood loss is minimal and recovery of the
patient is quicker with thrombotic complications occurring
less often. In addition post laparoscopic procedure adhesions
are rare compared to laparotomy procedures, pain is less,
restoration of the gastrointestinal tract function is quicker,
scarring much less and duration of in-hospital stay shorter.
Another advantage of laparoscopy is the ability to record the
procedure.
There are certain diﬀerences comparing total laparo-
scopic hysterectomy and laparoscopic assisted vaginal hys-
terectomy. In the ﬁrst, vaginal removal of the uterus
follows complete laparoscopic ligation and excision of all
the pedicles. In the second, ligation and excision of the
uterine arteries and the rest of the pedicles is performed
using the vaginal route. In more details, in total laparoscopic
hysterectomy thermal ligation and excision of the upper
and the lower brands of the uterine arteries is performed,
in subtotal laparoscopic hysterectomy thermal ligation and
excision only of the upper brands of the uterine arteries and
in laparoscopic assisted vaginal hysterectomy ligation and
excision of the main uterine arteries. Vaginal hysterectomy
on the other hand when indicated is a procedure with
excellent results.
The alternative to hysterectomy techniques, which
became available recently and most of them used advanced
technology have also very good results when compared
to hysterectomy. Most of them are indicated in case of
menorrhagia and are based on endometrial ablation. Even if
the control of blood loss is not 100% as it is in hysterectomy,
it is satisfactory. In cases of menorrhagia due to ﬁbroids
the alternative methods are based in the shrinkage of them
by tissue necrosis or disturbance to their blood supply.
The results in this case are less satisfactory when compared
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prolapse is the indication for hysterectomy, the results of
the alternative techniques are comparable and even better
than hysterectomy. The surgical removal of a uterus that has
otherwise no other pathology is an amputating operation
that oﬀers no extra beneﬁts when compared to ﬁxing the
uterus in its proper position and repairing the pelvic ﬂoor
system.
4. Conclusion
Hysterectomy, whatever the approach used (abdominal,
vaginal, laparoscopic), remains the gold standard in the
treatment of many uterine benign pathological conditions
but we have to encourage the new techniques which use
modern technologies and their results are promising and in
many cases comparable with hysterectomy.
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